Abstract:Tumor development and metastasis are facilitated by the complex interactions between cancer cells and their microenvironment, which comprises stromal cells and extracellular matrix (ECM) components, among other factors. Stromal cells can adopt new phenotypes to promote tumor cell invasion. A deep understanding of the signaling pathways involved in cell-to-cell and cell-to-ECM interactions is needed to design effective intervention strategies that might interrupt these interactions. In this review, we describe the tumor microenvironment (TME) components and associated therapeutics. We discuss the clinical advances in the prevalent and newly discovered signaling pathways in the TME, the immune checkpoints and immunosuppressive chemokines, and currently used inhibitors targeting these pathways. These include both intrinsic and non-autonomous tumor cell signaling pathways in the TME: protein kinase C (PKC) signaling, Notch, and transforming growth factor (TGF-β) signaling, Endoplasmic Reticulum (ER) stress response, lactate signaling, Metabolic reprogramming, cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) and Siglec signaling pathways. We also discuss the recent advances in Programmed Cell Death Protein 1 (PD-1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4), T-cell immunoglobulin mucin-3 (TIM-3) and Lymphocyte Activating Gene 3 (LAG3) immune checkpoint inhibitors along with the C-C chemokine receptor 4 (CCR4)- C-C class chemokines 22 (CCL22)/ and 17 (CCL17), C-C chemokine receptor type 2 (CCR2)- chemokine (C-C motif) ligand 2 (CCL2), C-C chemokine receptor type 5 (CCR5)- chemokine (C-C motif) ligand 3 (CCL3) chemokine signaling axis in the TME. In addition, this review provides a holistic understanding of the TME as we discuss the three-dimensional and microfluidic models of the TME, which are believed to recapitulate the original characteristics of the patient tumor and hence may be used as a platform to study new mechanisms and screen for various anti-cancer therapies. We further discuss the systemic influences of gut microbiota in TME reprogramming and treatment response. Overall, this review provides a comprehensive analysis of the diverse and most critical signaling pathways in the TME, highlighting the associated newest and critical preclinical and clinical studies along with their underlying biology. We highlight the importance of the most recent technologies of microfluidics and lab-on-chip models for TME research and also present an overview of extrinsic factors, such as the inhabitant human microbiome, which have the potential to modulate TME biology and drug responses.

The tumor microenvironment: shaping cancer progression and treatment response

Tumor microenvironment signaling and therapeutics in cancer progression

Unraveling the Tumor Microenvironment: Insights into Cancer Metastasis and Therapeutic Strategies

Tumor microenvironment as a complex milieu driving cancer progression: a mini review

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics

Targeting Tumor Microenvironment for Cancer Therapy

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

New horizons in tumor microenvironment biology: challenges and opportunities

Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications

The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited

Cancer-Specific Nanomedicine Delivery Systems and the Role of the Tumor Microenvironment: A Critical Linkage

Managing the TME to improve the efficacy of cancer therapy

Tumor Microenvironment: From Cervical Carcinogenesis to Therapeutic Advancements

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Role of tumor microenvironment in cancer progression and therapeutic strategy

Targeting Tumor Microenvironment by Small-Molecule Inhibitors

Tumor microenvironment: A playground for cells from multiple diverse origins

Nanoparticles Targeting and Remodeling Tumor Microenvironment for Cancer Theranostics.

Tumor microenvironment complexity and therapeutic implications at a glance